Becton, Dickinson and Company (NYSE:BDX) Shares Bought by Great Lakes Retirement Inc.

Great Lakes Retirement Inc. raised its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 14.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 3,674 shares of the medical instruments supplier’s stock after acquiring an additional 473 shares during the quarter. Great Lakes Retirement Inc.’s holdings in Becton, Dickinson and Company were worth $886,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Livelsberger Financial Advisory acquired a new stake in Becton, Dickinson and Company in the 3rd quarter worth about $26,000. Sound Income Strategies LLC boosted its stake in shares of Becton, Dickinson and Company by 35.8% in the third quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth approximately $45,000. Abound Wealth Management raised its stake in Becton, Dickinson and Company by 96.0% in the 2nd quarter. Abound Wealth Management now owns 196 shares of the medical instruments supplier’s stock valued at $46,000 after purchasing an additional 96 shares during the last quarter. Finally, Chilton Capital Management LLC lifted its holdings in Becton, Dickinson and Company by 1,233.3% in the 2nd quarter. Chilton Capital Management LLC now owns 200 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 185 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.8 %

BDX opened at $238.62 on Friday. The stock has a market capitalization of $68.96 billion, a PE ratio of 52.56, a P/E/G ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $262.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The business’s 50 day moving average price is $237.33 and its 200 day moving average price is $235.16.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. The company’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.96 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current year.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent research reports. Raymond James reduced their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Evercore ISI raised their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.